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ABSTRACT
Background Two recent studies identiﬁed a mutation
(p.Asp620Asn) in the vacuolar protein sorting 35 gene
as a cause for an autosomal dominant form of Parkinson
disease . Although additional missense variants were
described, their pathogenic role yet remains inconclusive.
Methods and results We performed the largest multi-
center study to ascertain the frequency and pathogenicity
of the reported vacuolar protein sorting 35 gene variants
in more than 15,000 individuals worldwide. p.Asp620Asn
was detected in 5 familial and 2 sporadic PD cases and
not in healthy controls, p.Leu774Met in 6 cases and 1
control, p.Gly51Ser in 3 cases and 2 controls. Overall
analyses did not reveal any signiﬁcant increased risk for
p.Leu774Met and p.Gly51Ser in our cohort.
Conclusions Our study apart from identifying the p.
Asp620Asn variant in familial cases also identiﬁed it in
idiopathic Parkinson disease cases, and thus provides
genetic evidence for a role of p.Asp620Asn in Parkinson
disease in different populations worldwide.
INTRODUCTION
There is increasing interest to try to identify
uncommon and rare genetic variants that increase
the risk of common diseases and that are difﬁcult
to identify using traditional genome-wide associ-
ation studies (GWAS) approaches.1 Rare variants
which are not mapped by GWAS can be identiﬁed
by using next generation sequencing, that is,
exome sequencing in large families with multiple
affected individuals.2 Exome sequencing is now
routinely used to identify rare mutations in famil-
ial forms of disease in diverse phenotypes.2
Two recent studies independently performed
exome sequencing in large families of Caucasian
descent, and identiﬁed a mutation in the vacuolar
protein sorting 35 (VPS35) gene as a possible cause
for an autosomal dominant form of Parkinson disease
(PD).3 4 In addition, several non-synonymous base
exchanges were identiﬁed, but their involvement in
disease pathogenesis remains inconclusive.
Furthermore, recently published studies provided con-
ﬂicting results regarding the role of VPS35 in PD.5–8
Here, we performed a large multi-centre study to
determine the frequency and pathogenicity of VPS35
variants in PD in diverse populations worldwide.
METHODS
Consortium
Investigators from the Genetic Epidemiology of
Parkinson disease Consortium were invited to par-
ticipate in this study. A total of 23 sites represent-
ing 19 countries from four continents agreed to
contribute DNA samples and clinical data for a
total of 15 383 individuals (8870 cases and 6513
controls). Control individuals underwent neuro-
logical examination and were excluded from the
study whenever there was clinical evidence for any
extrapyramidal disorder.
Genotyping
We selected seven non-synonymous variants
exactly as they were proposed.3 In addition, we
selected tag single nucleotide polymorphisms
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(SNPs) (HapMap Rel 28 phase II+III, Aug10, National Centre
for Biotechnology Information. B36 dbSNP b126; http://www.
hapmap.org) that cover the common genetic variants in the
VPS35 gene using an r2 threshold of 0.8–1.0 to select tag SNPs
for VPS35 gene. Using this strategy, we were able to capture 23
SNPs in a 40 kb region, including VPS35 (‘chr16:46 693 589–
46 723 144 based on hg 19’). Therefore, in total, 10 SNPs
located in the VPS35 were genotyped (including seven rare non-
synonymous and three common variants). Genotyping was
performed by a central genotyping core. Genotyping was per-
formed using a matrix-assisted laser desorption/ionisation
time-of-ﬂight mass spectrometry on a MassArray system
(Sequenom, San Diego, California, USA). Cleaned extension
products were analysed by a mass spectrometer (Bruker
Daltronic, Billerica, MA, USA) and peaks were identiﬁed using
the MassArray Typer 4.0.2.5 software (Sequenom). Assays were
designed by the AssayDesigner software 4.0 (Sequenom) with
the default parameters for the iPLEX Gold chemistry and the
Human GenoTyping Tools ProxSNP and PreXTEND
(Sequenom). All variants were genotyped in one multiplex
assay. The average call rate of the variants was >97%. The
local Ethics Committee approved the study. All participants
gave signed informed consent.
Statistical analysis
Logistic regression was used to test the association between
VPS35 and PD in our overall cohort. For common variants
(minor allele frequency >5%), we synthesised the effect esti-
mates using ﬁxed and random effects models. Fixed effect
models assume that the genetic effect is the same in popula-
tions from different sites and that observed differences are due
to chance alone. For associations showing between-study het-
erogeneity, ﬁxed effect estimates yield narrower CIs and smaller
p values as compared with random effects models, which
incorporate between-study heterogeneity.9 10 Random effects
models allow the genetic effects might be different due to
genuine heterogeneity that may exist across different sites.
Random effects calculations take into account the estimated
between-study heterogeneity. Cochran’s Q test of homogeneity
and the I2 metric were used to evaluate the between-site het-
erogeneity. The I2 metric ranges from 0% to 100% and mea-
sures the proportion of variability that is beyond chance.
Typically, estimates of I2<25% are considered to reﬂect little or
no heterogeneity, 25%–50% moderate heterogeneity, 50%–75%
large heterogeneity and >75% very large heterogeneity. The
overall main analysis considered all sites and populations irre-
spective of ancestry. For variants with minor allele frequency
<1%, an exact test was used to compare the frequency differ-
ences between cases and controls combining data across all 21
sites.
RESULTS
Characteristics of sites and overall database
Overall, 23 sites contributed a total of 8870 cases and 6513 con-
trols. Characteristics of all participating sites are shown in table
1. Most sites contributed participants of Caucasian ancestry
(N=19); four sites included participants of Asian ancestry. The
proportion of men and women ranged from 42% to 58% across
different participating sites (table 1). The median age at onset
of PD in our studied population was 61 years.
Rare variants
Overall, we observed p.Asp620Asn in seven cases, p.Leu774Met
in six cases and one control, p.Gly51Ser in three cases and two
controls. Details per site are shown in table 2. The controls
subjects carrying p.Leu774Met (P-13) and p.Gly51Ser (P-2 and
P-16) at the time of study sampling were 81, 84 and 76 years,
respectively. In Caucasian populations, the number of carriers
in cases and controls for the three variants were 5 versus 0
(pAsp620Asn), 4 versus 1 (pLeu774Met) and 3 versus 1
(p.Gly51Ser), respectively. In Asian descent populations, the
respective numbers were 2 versus 0 (p.Asp620Asn), 2 versus 0
(p.Leu774Met) and 0 versus 1 (p.Gly51Ser). Most interestingly,
two out of seven patients carrying the p.Asp620Asn variant
presented without any family history for PD. This represents
the ﬁrst evidence for reduced penetrance of the respective
variant initially attributed to autosomal dominant familial PD.
We did not observe any carriers for one variant (p.Arg524Trp)
in our cohort. Two non-synonymous variants (p.Met57Ile, p.
Thr82Arg) failed genotyping. By collapsing the rare variants
across different sites, we did not observe statistically signiﬁcant
increased risk for p.Leu774Met and p.Gly51Ser in our cohort
(see online supplementary table S1).
Overall data synthesis for common variants
Out of three tag SNPs, one SNP (rs3218745) failed genotyping.
We did not observe signiﬁcant association for any of common
variants with PD either with either ﬁxed effect or random
effect models (see online supplementary table S2). The OR
ranged from 0.96 to 0.99 and tight 95% CIs excluded modest
association effects. We observed no substantial heterogeneity
for the two genotyped SNPs, and also the Q test was non-
statistically signiﬁcant for common SNPs. Moreover, examining
the Caucasian or Asian populations separately did not change
our results (data not shown).
Clinical features
All PD patients who carried potential pathogenic variants (p.
Asp620Asn, p.Gly51Ser, p.Leu774Met) were clinically diagnosed
with PD (Online supplementary clinical analysis data). A few of
these (0.2%) affected individuals also have a positive family
history. Affected individuals exhibited classical symptoms of PD
(resting tremor, bradykinesia, rigidity) (table 2). The clinical
diagnosis of PD was made by movement disorder specialists
who used UK brain bank criteria for PD. Non-motor symptoms
were present in the majority of PD patients carrying a patho-
genic variant (table 2). Interestingly, hallucinations and demen-
tia were also observed in one asymptomatic carrier suggesting
clinical heterogeneity associated with VPS35. The identiﬁed
healthy carriers have not shown any sign of PD as yet (table 2).
DISCUSSION
We performed the ﬁrst multi-centre study to deﬁne the role of
the VPS35 gene (PARK17) in PD by assessing the frequency of
the reported non-synonymous variants in familial and sporadic
PD patients from different populations worldwide. Among
15 383 subjects genotyped, we found a pathogenic relevance for
p.Asp620Asn in different populations. Most interestingly, out
of seven subjects who carry p.Asp620Asn, two have a negative
family history. Therefore, our results provide additional evi-
dence that VPS35 is a rare cause of familial as well as the
common sporadic form of PD. In total, about 0.4% of PD cases
in diverse population were due to disease-associated variant in
the VPS35 gene. Our lack of supporting the role of common
variants of the VPS35 gene in PD is consistent with recently
published GWAS and also meta- analyses of GWAS of PD, as
none of these highlighted the role of common variability in
VPS35 gene as a risk factor for PD.11–15 The p.Asp620Asn
722 J Med Genet 2012;49:721–726. doi:10.1136/jmedgenet-2012-101155
Genotype-phenotype correlations
 group.bmj.com on April 23, 2013 - Published by jmg.bmj.comDownloaded from 
variant is located in the C-terminal region of the VPS35 protein
pointing that subtle structural changes might inﬂuence the
disease pathogenesis.3
The spectrum of proteins involved in PD aetiology has
grown considerably. This includes proteins that are related to
mitochondrial quality control (Parkin, PINK1 and DJ1), pro-
teins involved in protein aggregation (SNCA) (Synuclein,
MAPT) Microtubule associated protein Tau), and proteins
which are involved in sorting and degradation within endocytic
and autophagy pathways ((VDAC) Voltage dependent anion
channel, (GBA) Glucocerebrosidase gene, VPS35).16 17 So far,
very little is known about the speciﬁc role of VPS35 in PD,
except that it is hypothesised that it is involved in cargo recog-
nition as part of a retrograde complex recycling membrane pro-
teins from endosomes to the trans-Golgi network.3 4 Indeed, in
vitro and in vivo studies strongly implicate the role of VPS35
Table 1 Description of datasets contributed by each study site
Site Country N Case Control Male (%) Female (%) Mean AAO Mean Age at study Diagnostic criteria
Annesi Italy 394 197 197 204 (51.7%) 190 (48.2%) 61.5 63.7 UKPDBB
Brice France 505 272 233 302 (59.8%) 203 (40.1%) 47.6 57.8 UKPDBB
Bozi Greece 222 114 108 107 (48.1%) 115 (51.8%) 69.9 74.5 UKPDBB
Wszolek USA 1518 692 826 794 (52.3%) 724 (47.6%) 64.4 71.7 UKPDBB
Garraux Belgium 82 68 14 45 (54.8) 37 (45.1%) 62.1 69.6 UKPDBB
Hadjigeorgiou Greece 714 357 357 379 (53.0%) 335 (46.9%) 63.4 63.7 UKPDBB
Jeon Korea 749 408 341 314 (41.9%) 435 (58.0%) 57.6 NA UKPDBB
Opala Poland 629 352 277 340 (54.0%) 288 (45.7%) 50.2 68.1 UKPDBB
Lynch Ireland 740 368 372 340 (45.9%) 400 (54.0%) 50.5 70.7 UKPDBB
Lin Taiwan 320 160 160 160 (50%) 160 (50%) 62.0 70.8 UKPDBB
Facheris Italy 181 114 67 86 (47.5%) 95 (52.4%) 63.0 NA UKPDBB
Maraganore USA 1024 801 223 600 (58.5%) 361 (35.3%) 59 74.7 Bower
Mellick Australia 2024 1012 1012 1042 (51.4%) 981 (48.4%) 59 72.2 Bower
Morrison England 1120 766 354 606 (54.1%) 514 (45.8%) 66.1 NA UKPDBB
Mok China 436 260 176 264 (60.5%) 170 (38.9%) NA 63.5 UKPDBB
Aasly Norway 1278 656 622 721 (56.4%) 557 (43.5%) 58.8 72.9 UKPDBB
Wirdefeldt Sweden 299 83 216 147 (49.1%) 152 (50.8%) 65.8 71.4 Gelb
Van Broeckhoven Belgium 1010 501 509 500 (49.5%) 509 (50.3%) 60.5 66.3 Pals/Gelb
Rogaeva Canada 560 387 173 303 (54.1%) 257 (45.8%) 49.7 64.2 UKPDBB
Tan Singapore 391 194 197 244 (62.4%) 147 (37.5%) 59.7 54.0 UKPDBB
Hattori Japan 121 121 0 62 (51.2%) 59 (48.7%) NA NA UKPDBB
Gasser/Sharma Germany 760 760 0 479 (63.3%) 281 (36.9%) 58.9 NA UKPDBB
Toda Japan 306 227 79 161 (52.6%) 145 (47.3%) 57.8 65.1 UKPDBB
Total 15 383 8870 6513 59.5 67.6
AAO, Age at onset; NA: Not applicable.
Table 2 Clinical description of carriers of non-synonymous variants of vacuolar protein sorting 35 gene
Id Ethnicity Rare variant
Age at









P-1 Caucasian p.Asp620Asn 59 Classical PD + + + + + Negative Negative
P-2 Caucasian p.Gly51Ser NA Control − − − − − Negative Negative
P-3 Caucasian p.Gly51Ser NAV Classical PD + + + + + Dementia, visual
hallucinations
Negative
P-4 Caucasian p.Gly51Ser 55 Classical PD + + + + + Negative Negative
P-5 Caucasian p.Gly51Ser 49 Classical PD + + + + + Negative Negative
P-6 Caucasian p.Asp620Asn 37 Classical PD + + + + + Negative Positive
P-7 Caucasian p.Asp620Asn 59 Classical PD + + + + + Negative Positive
P-8 Caucasian p.Asp620Asn 55 Classical PD + + + + + Negative Positive
P-9 Caucasian p.Asp620Asn 66 Classical PD + + + + + Negative Positive
P-10 Caucasian p.Leu774Met 41 Classical PD + + + + + Negative Positive
P-11 Caucasian p.Leu774Met 65 Classical PD + + + + + Negative Positive
P-12 Caucasian p.Leu774Met 65 Classical PD + + + + + Disturbance of gait
and balance
Positive
P-13 Caucasian p.Leu774Met NA Control − − − − NA - Negative







52 Classical PD + + + + + Negative Negative
P-16 Asian p.Gly51Ser Control − − − − − – Negative
P-17 Asian p.Leu774Met 75 Classical PD + + + + + Negative Negative
P-18 Asian p.Asp620Asn 43 Classical PD + + + + + Mild cognitive
impairment
Positive
NA, not applicable; NAV, not available; PD, Parkinson disease; +positive; −negative.
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gene in neurodegeneration. For example, reduced levels of
VPS35 have been found in affected brain regions of Alzheimer
disease (AD) patients18 and loss of VPS35 function has been
shown to increase the levels of amyloid β and cause synaptic
impairment in a mouse model of AD. Furthermore, variants in
another member of the VPS family and substrate of retromer
complex, SORL1, have been implicated in AD.19
In this study, we have focused only on non-synonymous
variants identiﬁed by Zimprich and colleagues.3 Of note, we
conﬁrmed the pathogenic relevance of the p.Asp620Asn
variant which was identiﬁed by both studies for familial cases
and in sporadic PD. Recently, published studies also identiﬁed
p.Asp620Asn mutations in PD,6 20 thus providing support to
the role of p.Asp620Asn in PD. In our study, clinically, the
symptomatic carriers showed a broad spectrum of clinical phe-
notypes ranging from typical PD to (DLB) Dementia with
Lewy body, so longitudinal evaluation of carriers at risk will
provide unique information on the natural course of the
disease caused by VPS35. Even though our data support the
role of p.Asp620Asn variant in PD, given the fact that the fre-
quency in diverse population is far below <1%, it is likely to
be a rare cause of PD worldwide. Nevertheless, sequencing of
families is encouraged for identifying additional missense var-
iants which may provide mechanistic insight into the causes
of PD.
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